Clinical Trials

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07000149 2026-03-10

eVOLVE-RCC02

1,116 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT05568095 2026-03-04

STAR-221

1,040 enrolled

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06097728 2026-03-04

eVOLVE-Meso

Other solid neoplasmThoracic

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT05907122 2026-02-27

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

256 enrolled

Melanoma

NCT07431281 2026-02-24

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

2,130 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

NCT04039607 2026-02-19

CheckMate 9DW

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT03143153 2026-02-17

CheckMate 648

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

NCT07405164 2026-02-12

MK-6482-043

Phase 3 Not yet recruiting

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

855 enrolled

Urinary Bladder Neoplasms

NCT06054555 2026-01-12

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

633 enrolled

Melanoma

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT03215706 2025-12-17

CheckMate 9LA

719 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT05111626 2025-12-15

FORTITUDE-102

515 enrolled

Stomach Neoplasms

NCT05317858 2025-12-10

LIMITLESS

30 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03383458 2025-11-21

CheckMate 9DX

545 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02743494 2025-11-18

CheckMate 577

794 enrolled 13 charts 1 FDA

Advanced Cancer

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

Carcinoma, Non-Small-Cell Lung

NCT03906071 2025-10-21

SAPPHIRE

577 enrolled 22 charts

Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT02632409 2025-10-16

CheckMate 274

709 enrolled 13 charts 1 FDA

Various Advanced Cancer

NCT03520686 2025-10-16

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

1,538 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04025879 2025-10-16

A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

461 enrolled 18 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04810078 2025-10-09

CheckMate-67T

681 enrolled 1 FDA

Carcinoma, Renal Cell

NCT04008030 2025-10-03

CheckMate 8HW

839 enrolled 22 charts 1 FDA

Colorectal Neoplasms

NCT04674683 2025-09-24

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

450 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04149574 2025-09-16

CheckMate 7G8

Phase 3 Terminated

13 enrolled 11 charts

Urinary Bladder Neoplasms

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT04099251 2025-08-27

CheckMate76K

790 enrolled 18 charts 1 FDA

Melanoma

NCT05625399 2025-08-24

RELATIVITY-127

579 enrolled

Melanoma

NCT04987203 2025-08-22

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

343 enrolled

Carcinoma, Renal Cell, Disease Progression

NCT02872116 2025-08-07

CheckMate649

2,031 enrolled 19 charts 1 FDA

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT06640530 2025-07-08

UNIVERSE

392 enrolled

Melanoma

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT02667587 2025-06-18

CheckMate548

716 enrolled 15 charts

CNS

Brain Neoplasms

NCT04100018 2025-06-12

CheckMate 7DX

1,030 enrolled 25 charts

Prostatic Neoplasms

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

906 enrolled 16 charts 1 FDA

Melanoma

NCT03635983 2025-04-01

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

783 enrolled 24 charts

Melanoma

NCT02576509 2025-02-17

An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma

743 enrolled 16 charts

Carcinoma, Hepatocellular

NCT04109066 2025-01-08

CheckMate 7FL

521 enrolled 17 charts

Breast

Breast Neoplasms, Neoplasms

NCT03138512 2024-12-18

CheckMate 914

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04340193 2024-11-26

CheckMate 74W

26 enrolled 15 charts

Liver Neoplasms

NCT02613507 2024-11-19

CheckMate 078

504 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT06022861 2024-09-19

A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

510 enrolled

Esophageal Squamous Cell Carcinoma

NCT05144854 2024-09-05

A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

626 enrolled

Stomach Neoplasms

NCT03195491 2024-07-18

CheckMate870

400 enrolled 19 charts